Longeveron (LGVN) Stock

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer's disease (AD) Lomecel-B™  capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD Immunomodulatory and pro-vascular effects of Lomecel-B™  in mild AD potentially driven by ability to exert MMP14 inhibition which may protect TIE2 receptor integrity in human AD patients MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that its submission entitled “Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease” was presented as a late breaking poster presentation at the 17th edition of the Clinical Trials on Alzheimer's Disease Conference (CTAD24) taking place October 29 -November 1, 2024 in Madrid, Spain. “As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B™ offers the potential to address the underlying pathology of Alzheimer's disease,” said Joshua Hare, M.D.

Oral presentation highlights findings that patients treated with Lomecel-B TM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2% heart transplantation rate ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatment Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation ELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-B TM as a potential adjunct therapy for HLHS versus standard of care alone MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clinical trial were featured in an oral presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting taking place October 27-28, 2024 in Chicago, Illinois. “HLHS is a devastating disease for patients and their families, so I am impressed and very encouraged to see the continued long-term survival of patients treated with Lomecel-BTM in the ELPIS I study,” said Sunjay Kaushal, M.D.

Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer's Disease Conf (CTAD24).

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society Mtg.

Wa'el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th

Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.

Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.

MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.

Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quarter Financial Results Conference Call.